drugset
drugset / Trial / NCT03303469

Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging

NCT03303469 ↗

Phase 2 Terminated 3 enrolled University of Alabama at Birmingham
NaSingle-groupOpen-labelDiagnostic

Summary

\[18F\] FMISO Positron Emission Tomography (PET) to determine hypoxia in patients with HCC treated with TACE.

Timeline

Start
2017-10-30
Primary completion
2021-01-06
Completion
2021-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject F-MISO Diagnostic / imaging agent — —

Indications

hepatocellular carcinoma